Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
Breast Cancer
DRUG: Nivolumab 360mg|DRUG: Paclitaxel 80mg/m^2|DRUG: Doxorubicin 60mg/m^2|DRUG: Cyclophosphamide 600mg/m^2|DRUG: Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|DRUG: Trastuzumab 8mg/kg and 6 mg/kg|DRUG: Pertuzumab 840mg and 420mg
Number of Participants Who Had a Pathological Complete Response (pCR), pCR is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy (ypT0/Tis ypN0)., up to 16 weeks|Number of Participants Who Had a Pathological Complete Response (pCR), pCR is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy (ypT0/Tis ypN0)., up to 1 year
The purpose of this study is to determine whether the addition of nivolumab to chemotherapy improves pathologic complete response (pCR) in the breast and post-therapy lymph nodes evaluated histologically (ypT0/Tis ypN0) in patients with inflammatory breast cancer (IBC).